The role of the neurokinine 1 receptors (NK1R) and its endogenous ligand, the neuropeptide substance P (SP) in the pathophysiology and treatment response of anxiety and depression has been controversial. In a new study, however, mice with a targeted inactivation of the NK1R show a phenotype that is associated with anxiety-related behaviors and stress responses. Since this behavioral phenotype was associated with an increase in serotonergic function, NK1R knockout mice represent a systematic model for advanced investigations of SP/NK1R and serotonin system interaction in anxiety responses. The availability of an increasing number of knockout mouse anxiety models as well as integration of emerging tools and technologies for genetic analysis will provide the groundwork for the genetic dissection of anxiety and related disorders.
1 make a strong argument for a critical role of the SP/NK1R system in the modulation of anxiety-related behaviors in mice. Complete knockout of the NK1R produced a phenotype that is associated with an increase of fear and anxiety in the Elevated Plus Maze, Novelty Suppressed feeding, and Maternal Separation paradigms. Results derived from pharmacologic, immunohistochemical, autoradiographic, endocrine, and electrophysiological studies, convincingly identify the serotonergic system as a key player in anxiety-related responses to NK1R knockout, while an association of the NK1R with noradrenergic neurons seems to mediate this behavioral phenotype.
GENETIC DISSECTION OF ANXIETY
Anxiety and related behaviors are influenced by genetic factors but the genetic component is highly complex, polygenic, and epistatic. Although a large number of genes which may contribute to the genetic variance of fearfulness and anxiety or modify the phenotypic expression of pathologic anxiety are currently under investigation, molecular genetics in humans has so far failed to identify a genomic variation that consistently contributes to susceptibility of anxiety disorders. For a long time the limited availability of appropriate animal models has hindered research in complex traits related to anxiety. Pharmacologic manipulations have been used to induce behaviors that simulate aspects of human anxiety disorders in laboratory animal models; however, these models represent pheno− copies and do not reflect genetic causes of aberrant behavior. The ability to create and analyze gene deletions rapidly, as well as to map novel behavioral mutations within these deletion complexes, is expediting systematic functional analysis of genes that control behavior in mice, as well as characterization of corresponding genes in humans.
A complementary approach to genetic studies of anxiety and related disorders in humans involves investigation of genes and their protein products implicated in the brain neurocircuitry of fear and anxiety in animal models. Based on the increasing body of evidence that genetically driven variability of expression and function of proteins that regulate the function of brain neurotransmitter systems (eg, receptors, ion channels, transporters, and enzymes), is associated with complex behavioral traits, research is now putting strong emphasis on the molecular psychobiological basis of anxiety-related behaviors in rodents. Conditioning of fear and anxiety involves pathways transmitting information to and from the amygdala to various neural networks that control the expression of aggressive or defensive reactions, including behavioral, autonomic nervous system, and stress hormone responses. 2 While pathways from the thalamus and cortex (sensory and prefrontal) project to the amygdala, inputs are processed within intra-amygdaloid circuitries and outputs are directed to the hippocampus, brain stem, hypothalamus, and other regions. Thus, the amygdala-associated neural network is critical to integration of the 'fight or flight' response. Identification of the molecular component of neural circuits involved in fear and anxiety is currently leading to new candidate genes of presumed pathophysiologic pathways, in addition to candidates that are commonly derived hypothesized pathogenetic mechanisms of the disorder or from clinical observations of therapeutic response.
MODELING ANXIETY-RELATED TRAITS IN MICE
Individual differences in anxiety-related traits, and the ultimate behavioral consequences of the 'fight or flight' response, are relatively enduring, continuously distributed, as well as substantially heritable, although they seem to result from additive or nonadditive interaction of genetic variations with environmental influences. While studies of the patterns of inheritance indicate that various dimensions are likely to be influenced by many genes making polygenic or quantitative traits, it likewise documents the significance of environmental factors. While current views emphasize the joint influence of genes and environmental sources, the complexities of gene-gene and gene-environment interactions represent research areas in their infancy. 'Fight or flight' responses which are the consequence of predominance of either aggression or anxiety seem to delineate a biologically based model of dispositions to both normal and pathological functioning, with a continuum of genetic risk underlying behavioral dimensions that extend from normal to abnormal. This vista has therefore increasingly encouraged the pursuit of dimensional and quantitative approaches to behavioral genetics. 3 While quantitative genetics has focused on complex, quantitatively distributed
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Traditionally, quantitative genetic research in animal models consisted primarily of inbred strain and selection studies. While comparisons between different inbred strains of mice expose remarkable differences in measures of anxiety-related behavior, such as performance in the Open Field or Elevated Plus Maze paradigm, differences within strains can be attributed to environmental influences. Inbred and recombinant inbred strain studies are highly efficient in dissecting genetic influences, for investigating interactions between genotype and environment, and for testing the disposition-stress model. Selective breeding of mice for many generations produces differences between high and low anxiety lines that steadily increase each generation. Selection studies of behavioral traits strongly suggest a genetic influence and that many genes contribute to variation in behavior. Mice strains that have been selectively bred to display a phenotype of interest are currently being used to identify genetic loci that contribute to behavioral traits. The quantitative trait locus (QTL) approach has been applied with some success to a trait in mice called 'emotionality'. 4 Crosses between the high and low activity selected mouse lines yielded three QTL regions that appear to be related to various measures of fearfulness. A modified QTL strategy that uses recombinant inbred mouse strains produced candidate QTLs for Open Field fearfulness. 5 However, such linkage analyses provide only a rough chromosomal localization, whereas the next step, identifying the relevant genes by positional cloning, remains a challenging task. 6 Since mice and humans share many orthologous genes mapped to synthenic chromosomal regions, it is conceivable that individual genes identified for one or more types of murine anxiety-related behavior may be developed as animal models for human anxiety. Following chromosomal mapping of polymorphic genes and evaluation of gene function using knockout mutants, behavioral parameters, including the type of anxiety, measure of anxiety, test situation and opponent type are investigated. Thus, the combination of elaborate genetic and behavioral analyses results in the identification of many genes with effects on variation and development of murine anxiety-related behavior and, ultimately, mouse QTL research is likely to generate candidate QTL for human anxiety disorders.
Recent advances in gene targeting including constitutive or conditional knockout techniques are increasingly impacting upon our understanding of the neurobiologic basis of anxiety-related behavior in mice. 7 However, the majority of neural substrates and circuitries that regulate emotional processes or cause anxiety disorders remain remarkably elusive. Among the reasons for the lack of progress are several conceptional deficiencies regarding the psychobiology of fear and anxiety, which make it difficult to develop and validate reliable models. The clinical presentation of anxiety disorders and the lack of consensus on clinical categories further complicates the development of mouse models for specific anxiety disorders. The dilemma that no single paradigm mimics the diagnostic entities or treatment response of anxiety disorders may reflect the inadequacy of classification rather than failure to develop valid mouse models.
Various approaches have been employed to study anxietyrelated traits in mice and the majority postulate that aversive stimuli, such as novelty or potentially harmful environments induce a central state of fear and defensive reactions, which can be assessed and quantified through physiologic and behavioral paradigms. 8 While substantial similarities between human and murine avoidance, defense or escape response exist, it remains obscure whether mice also experience subjective anxiety and associated cognitive processes similar to humans or whether defense responses represent pathological forms of anxiety in humans. In general, pathological anxiety may reflect an inappropriate activation of normally adaptive, evolutionarily conserved defense reaction. It should therefore be practicable to elucidate both physiologic and pathologic anxiety by studying avoidant and defensive behavior in mice using a broad range of anxiety models to ensure comprehensive characterization of the behavioral phenotype.
WINNER BY KNOCKOUT
The design of a mouse model partially or completely lacking a gene of interest during all stages of development (constitutive knockout) is among the prime strategies directed at elucidating the role of genetic factors in fear and anxiety. Paralleling the critical role of the serotonin (5HT) system in anxiety-related responses to NK1R knockout, key components of serotonergic neurotransmission, such as the 5HT 1A receptor, have long been implicated in the modulation of anxiety as well as in the mode of action of anxiolytic drugs. 5HT 1A receptors operate both as somatodendritic autoreceptors and as postsynaptic receptors. Somatodendritic 5HT 1A autoreceptors are predominantly located on 5HT neurons and dendrites in the midbrain raphe complex and their activation by 5HT or 5HT 1A agonists decreases the firing rate of serotonergic neurons and subsequently reduces the release of 5HT from nerve terminals. Postsynaptic 5HT 1A receptors are widely distributed in forebrain regions that receive serotonergic input, notably in the cortex, hippocampus, and hypothalamus. Their activation results in neuronal inhibition, the consequences of which are not well understood, and in physiological responses that depend upon the function of the target cells (eg activation of the hypothalamic pituitary adrenocortical system). At the end of 1998, a series of three papers reported the generation of mice with a targeted inactivation of the 5HT 1A receptor. [9] [10] [11] Functional 5HT 1A receptor knockout was confirmed by a complete lack of 5HT 1A receptor binding in brain of nullmutant mice, with intermediate binding in heterozygote mice.
Mice with a targeted inactivation of the 5HT 1A receptor consistently display a spontaneous phenotype that is associated with a gender-modulated and gene/dose-dependent increase of anxiety-related behaviors. With the exception of an enhanced sensitivity of terminal 5HT 1B receptors and www.nature.com/tpj downregulation of GABA-A receptors, 12 no major neuroadaptational changes were detected. Noteworthy is that this behavioral phenotype was observed in animals in which the mutation was bred into mice of Swiss-Webster, C57BL/6J and 129/Sv backgrounds, solidly substantiating the assumption that this behavior is an authentic consequence of reduced or absent 5HT 1A receptors. While all research groups used Open Field exploratory behavior as a model for assessing anxiety, two groups confirmed that 5HT 1A knockout mice had increased anxiety by using other models, the Elevated Zero Maze or Elevated Plus Maze test. These ethologically-based conflict models test fear and anxiety-related behaviors based on the natural tendencies for rodents to prefer enclosed, dark spaces vs their interest in exploring novel environments.
Activation of presynaptic 5HT 1A receptors provide the brain with an autoinhibitory feedback system controlling 5HT neurotransmission. Thus, enhanced anxiety-related behavior most likely represents a consequence of increased terminal 5HT availability resulting from the lack or reduction in presynaptic somatodendritic 5HT 1A autoreceptor negative feedback function. Indirect evidence for increased presynaptic serotonergic activity is provided by the compensatory upregulation of terminal 5HT 1B receptors. This mechanism is also consistent with recent theoretical models of fear and anxiety that are primarily based upon pharmacologically-derived data. The cumulative reduction in serotonergic impulse flow to septohippocampal and other limbic and cortical areas involved in the control of anxiety is believed to explain the anxiolytic effects of ligands with selective affinity for the 5HT 1A receptor in some animal models of anxiety-related behavior. This notion is based, in part, on evidence that 5HT 1A agonists (eg 8-OH-DPAT) and antagonists (eg WAY 100635) have anxiolytic or anxiogenic effects, respectively. However, to complicate matters further, 8-OH-DPAT has anxiolytic effects when injected in the raphe nucleus, whereas it is anxiogenic when applied to the hippocampus. Thus, stimulation of postsynaptic 5HT 1A receptors has been proposed to elicit anxiogenic effects, while activation of 5HT 1A autoreceptors is thought to induce anxiolytic effects via suppression of serotonergic neuronal firing resulting in attenuated 5HT release in limbic terminal fields.
Enhanced serotonergic activity may also be implicated in increased anxiety-related behaviors recently found in 5HT transporter-deficient mice. 13 These findings are consistent with other evidence suggesting that increased 5HT availability may contribute to increased anxiety in rodents, and the studies reporting that anxiety-related traits in humans are associated with allelic variation of 5HT transporter function.
14 Mice with a disrupted 5HT transporter gene have been suggested as an alternative model to pharmacological studies of SSRI-evoked antidepressant and anxiolytic mechanisms to assess the hypothesized association between 5HT uptake function and 5HT 1A receptor desensitization. 15 Excess serotonergic neurotransmission in mice lacking 5HT transport results in desensitized and, unlike observations following SSRI administration, downregulated 5HT 1A receptors in the midbrain raphe complex but not in the hippocampus 16 and is suspected to play a role in the increased anxietyrelated and antidepressant-like behaviors in these mice using the Light-Dark and Elevated Zero Maze paradigms, and Tail Suspension paradigms. In contrast to 5HT 1A -deficient mice, anxiety-related behavior, which can be reversed by anxiolytics of the benzodiazepam type, is more pronounced in female 5HT transporter null mutants.
Morphological analyses of cortical and subcortical structures, where 5HT has been suggested to act as a differentiation signal, revealed an impact of 5HT transporter inactivation on the formation and plasticity of brain structures. 17 The evidence that changes in 5HT system homeostasis exert long-term effects on development and adult plasticity of brain may be an important step forward in establishing the psychobiological groundwork for a neurodevelopmental hypothesis of fearfulness, negative emotionality, and anxiety disorders. Although there is converging evidence that serotonergic dysfunction contributes to anxiety-related behavior, the precise mechanism that renders 5HT 1A receptor and 5HT transporter-deficient mice more anxious remains to be elucidated. While increased 5HT availability and activation of other serotonergic receptor subtypes that have been shown to mediate anxiety (eg 5HT 2C receptor) may contribute to increased anxiety in rodent models, multiple downstream cellular pathways or neurocircuits, including noradrenergic, GABAergic, glutamatergic, and peptidergic transmission, as suggested by overexpression or targeted inactivation of critical genes within these systems, have been implicated to participate in the processing of this complex behavioral trait. Recent work has therefore been focused on a large number of genes that have known relevance in the neurocircuitries of fear and anxiety, although the knockout of some genes that appear not directly to be involved in anxiety may also lead to an anxiety-related phenotype (Table 1) .
THE GOAL: GENETIC DISSECTION OF ANXIETY DISORDERS
Progress in the genetics of anxiety-related traits and anxiety disorders in humans will eventually be accelerated by closer integration of molecular neuroscience and genetic approaches. Future research directions will take advantage of the completion of sequencing the human and mouse genome coinciding with the revolution in bioinformatics, and integration of emerging tools and technologies for genetic analysis will provide the groundwork for an advanced stage of gene identification and functional studies. Other advanced genetic and genomic technologies include quantitative methods to identify anxiety susceptibility genes, DNA and protein microarrays to study gene expression, and techniques for efficient genome-wide mutagenesis that precede high-throughput behavioral phenotyping in the mouse. However, several conceptual refinements still need to be adopted. First, for detection of small gene effects, a dimensional, semi-quantitative approach to behavioral phenotypes arising from standardized trait assessment is needed. Established are two parallel definitions of anxiety pheno-
The Pharmacogenomics Journal types: categorical diagnoses (eg, panic disorder, social phobia) and dimensional traits (eg, anxious temperament, behavioral inhibition, negative emotionality). Given the limitation of the diagnostic approach future studies will require extended, homogeneous, and ethnically matched samples. With recent advances in molecular genetics, the rate-limiting step in identifying susceptibility genes has become a definition of (endo)phenotypes. Thus, investigation of genetic differences associated with variation along behavioral dimensions within diagnostic boundaries will be a useful complement to the traditional strategy of looking for genetic differences between categorically-defined disease entities.
Second, more functionally relevant polymorphisms in genes within a single neurotransmitter system, or in genes which comprise a functional unit in their concerted actions, need to be identified and assessed in both large population and family-based association studies to avoid stratification and to dissect complex epigenetic interaction of several loci. Further studies using refined linkage strategies, association techniques, and single nucleotide polymorphism (SNP) analysis, will be especially useful in the characterization of the genetic components of anxiety disorders. Based on the first draft sequence of the human genome, more than 1.4 million SNPs have been identified. 18 Large-scale association studies that couple the genotyping of functional SNPs with linkage disequilibrium mapping in chromosomal regions implicated in linkage studies, is an approach complementary to classical linkage analyses. Its success will depend on the availability of SNPs in the coding or regulatory regions of a large number of candidate genes as well as knowledge of the average extent of linkage disequilibrium between SNPs, the development of high-throughput technologies for genotyping SNPs, identification of protein-altering SNPs by cDNA and protein microarray-assisted expression analysis, and collection of DNA from well-phenotyped patients.
Third, genetic influences are not the only pathway that leads to individual differences in personality dimensions, behavior, and psychopathology. Complex traits are most likely to be generated by a complex interaction of environmental and experimental factors with a number of genes and their products. The resolution of epistatic interactions in behavior is among the last frontiers of genetic research. Even pivotal regulatory proteins of cellular pathways and neurocircuits have a modest impact, while noise from nongenetic mechanisms obstructs identification of relevant gene variants. Although current methods for the detection of gene-environment interaction in anxiety disorders are largely indirect, the most relevant consequence of gene identication for anxiety-related traits may be that it will provide the tools required to systematically clarify the effects of gene-environment interaction.
Finally, future benefits will stem from the potential development of techniques involving molecular cell biology, transgenics, and gene transfer technology that could facilitate novel drug design. Paralleling the resolution of genegene and gene-environment interactions and the fading dogma that neurons are highly vulnerable and their GABA, ␥-amino butyric acid; GAD65, 65-kDa isoform of glutamic acid decarboxylase; MAOA, monoamine oxidase A; COMT, catechol-O-methyltransferase; AC VIII; adenylyl cyclase type VIII; CamKII, calcium-calmodulin kinase II; CRH corticotrophin-releasing hormone; CREM, cAMP-responsive element modulator; ApoE, apolipoprotein E; NCAM, neural cell adhesion molecule; FMR1, Fragile X syndrome gene. ↑/↓, increase/decrease in anxiety-related behavior.
capacity for regeneration, reproducibility, and plasticity is limited, it is being realized that gene-based treatment strategies may eventually be applicable to complex disorders. While targeting gene regulation or gene transfer approaches are quite appealing, no presently available technique meets www.nature.com/tpj the rigorous requirements obligatory for human trials, the technical prerequisites are being developed at an incredible pace, thus raising modest hopes for a beneficial application of these strategies in some forms of chronic and treatmentresistant anxiety disorders.
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